Sanofi India has received USFDA approval for its drug Calbivi which is tested to treat a rare blood-clotting disorder in adults in combination with standard-of-care treatments. The drug Calbivi which has Caplacizumab as active substance was initially developed by Ablynx, a Belgium biotech firm that Sanofi acquired in 2018.
The company has already received approvals in Europe, as it is a life-threatening, autoimmune disorder characterized by clot formation in small blood vessels throughout the body, cutting off blood supply to various body parts and potentially causing strokes and heart attacks.
Company Profile : Sanofi India Ltd
Leave a Reply